The COVID-19 pandemic has had a significant impact on first- and second-quarter revenues of medical device companies, with the spine and orthopedic industry taking a particularly seismic blow.
Here is a breakdown of key quarterly results published by Zimmer Biomet, Stryker, Globus Medical and Medtronic this year, along with the year-over-year percentage change:
First quarter
Net sales: $1.78 billion (-9.7 percent)
Global hips sales: $433 million (-10.5 percent)
Sports medicine, extremities and trauma sales: $333 million (-6.5 percent)
Knees sales: $629.8 million (-9.3 percent)
Dental, spine and craniomaxillofacial and thoracic sales: $252 million (-12.4 percent)
Net sales: $3.6 billion (+2 percent)
Knees sales: $432 million (+1.7 percent)
Hips sales: $316 million (+5.9 percent)
Trauma and extremities sales: $392 million (+0.8 percent)
Neurotechnology and spine sales: $700 million (+0.7 percent)
Total sales: $190.6 million (+4.2 percent)
U.S. sales (including robotics): $158.4 (+7.4 percent)
International sales: $32.1 million (-9.3 percent)
Net income: $25.9 million (-21.9 percent)
Second quarter
Net sales: $1.23 billion (-38.3 percent)
Global hips sales: $329.7 million (-31.1 percent)
Sports medicine, extremities and trauma sales: $252.6 million (-29.2 percent)
Knees sales: $374.2 million (-46.8 percent)
Dental, spine and craniomaxillofacial and thoracic sales: $182.5 million (-37.6 percent)
Net sales: $2.8 billion (-24.3 percent)
Knees sales: $241 million (-45.2 percent)
Hips sales: $216 million (-37.1 percent)
Trauma and extremities sales: $330 million (-16.4 percent)
Neurotechnology and spine sales: $546 million (-29.6 percent)
Total sales: $148.9 million (-23.4 percent)
U.S. sales (including robotics): $125.2 million (-21.8 percent)
International sales: $23.8 million (-31.2 percent)
Net loss: $20.8 million (-154.6 percent)
Medtronic fourth quarter (reported May 20, 2020)
Total revenue: $6 billion (-26 percent)
Spine revenue: $480 million (-31 percent)
Brain therapies revenue: $615 million (-26 percent)
Specialty therapies revenue: $197 million (-44 percent)
Pain therapies revenue: $198 million (-42 percent)